Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Shares Soar on Down Syndrome Test Results

NEW YORK (GenomeWeb News) – Shares of Sequenom were up nearly 34 percent, to $27.50, in mid-afternoon trading today after the company disclosed yesterday that its SEQureDx test for Down syndrome successfully tested for Trisomy 21 in 219 patients with no false positives or negatives.
The company also announced yesterday that it will acquire the CLIA-certified Center for Molecular Medicine for $4 million, putting it on schedule to launch the Down syndrome test in the first half of 2009.  
The results disclosed yesterday follow previous positive findings that the company announced in June and support the potential for the test to be used in the first trimester, the company said.
Sequenom said that it plans to do additional testing on 3,000 to 5,000 women and the results of this study should be released next June.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.